Preference for Long-Acting Injectable PrEP Compared With Daily Oral PrEP Among Transgender Women in the U.S.: Findings From a Multisite Cohort

Preference for Long-Acting Injectable PrEP Compared With Daily Oral PrEP Among Transgender Women in the U.S.: Findings From a Multisite Cohort

Introduction: Pre-exposure prophylaxis (PrEP) use among transgender women in the U.S. has not reached levels optimal to change the trajectory of the HIV epidemic owing to multilevel barriers. Long-acting injectable PrEP received Food and Drug Administration approval in 2021 and may potentially addre...

Full description

Bibliographic Details
Main Authors: Erin E. Cooney, PhD, MSPH, Sari L. Reisner, ScD, MA, Tonia C. Poteat, PhD, MPH, PA-C, Asa E. Radix, MD, PhD, MPH, Kenneth H. Mayer, MD, Chris Beyrer, MD, MPH, Meg Stevenson, MSPH, Rodrigo A. Aguayo-Romero, PhD, Jason S. Schneider, MD, Andrew J. Wawrzyniak, PhD, Christopher M. Cannon, MPH, Carolyn A. Brown, PhD, MPH, Leigh Ragone, MS, Vani Vannappagari, PhD, Andrea L. Wirtz, PhD, MHS
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:AJPM Focus
Subjects:
Pre-exposure prophylaxis
transgender women
long-acting PrEP
injectable PrEP
HIV
U.S.
Online Access:http://www.sciencedirect.com/science/article/pii/S277306542500001X

Internet

http://www.sciencedirect.com/science/article/pii/S277306542500001X

Similar Items